Eli Lilly and Company (NYSE:LLY) Shares Purchased by Colonial River Wealth Management LLC

Colonial River Wealth Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 194.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,616 shares of the company’s stock after acquiring an additional 1,067 shares during the quarter. Colonial River Wealth Management LLC’s holdings in Eli Lilly and Company were worth $942,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in LLY. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $3,416,206,000. Moneta Group Investment Advisors LLC increased its stake in Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after buying an additional 5,440,731 shares during the period. Morgan Stanley increased its stake in Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the period. Imprint Wealth LLC increased its stake in Eli Lilly and Company by 53,716.8% during the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock worth $175,120,000 after buying an additional 1,747,946 shares during the period. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $445,944,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of the stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $630.28, for a total value of $9,068,468.64. Following the completion of the transaction, the insider now owns 99,754,422 shares in the company, valued at approximately $62,873,217,098.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 195,055 shares of company stock worth $125,254,657 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.4 %

Eli Lilly and Company stock traded up $3.41 during trading on Tuesday, reaching $763.96. The company had a trading volume of 2,552,667 shares, compared to its average volume of 3,221,156. Eli Lilly and Company has a 12-month low of $342.30 and a 12-month high of $800.78. The stock’s 50 day moving average price is $739.63 and its two-hundred day moving average price is $641.00. The firm has a market capitalization of $725.88 billion, a price-to-earnings ratio of 131.72, a PEG ratio of 1.71 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.09 earnings per share. As a group, equities analysts expect that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Morgan Stanley increased their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $700.00.

View Our Latest Stock Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.